Table 4.
Results of Autologous Hematopoietic Stem Cell Transplant in Pediatric Relapsed/Refractory Aggressive B-Cell Lymphoma
| Author (Reference) | N. Patients | Age (Years) | Years | Disease Status Before HSCT | Outcome (Years) |
|---|---|---|---|---|---|
| Loiseau (1991)68 | 24 auto (B-NHL 16) | < 18 | NR | NR | OS 33% (NR) |
| Bureo (1995)69 | 46 (auto 32, allo 14) (B-NHL 25) | < 18 | NR | NR | EFS 58% (NR) |
| Philip (1993)72 | 15 (auto 14, allo 1) | < 18 | 1984–1987 | NR | EFS 27% (4) |
| Landestein (1997)77 | 89 auto | < 18 | 1979–1991 | CR 24, PR 51, Res 14 | EFS 39.4% (5) |
| Won (2006)70 | 12 auto (BL 6, DLBCL 6) | < 18 | 1997–2004 | CR, no CR | EFS BL 66%; DLBCL 55% (2) |
| Gross (2010)78 | 93 (auto 52, allo 41) BL/BAL 41 (auto 17, allo 24) DLBCL 52 (auto 35, allo 17) |
< 18 | 1990–2005 | NR |
BL/BAL: EFS auto 27%; allo 31% (5) DLBCL: EFS auto 50%; allo 52% (5) |
| Harris (2011)73 | 10 auto (B-NHL) | < 21 | - | NR | EFS 70% (3) |
| Giulino-Roth (2013)71 | 36 (auto 15, allo 21) (B-NHL 9) | < 18 | 1982–2004 | NR | DFS 53% auto and allo (10) |
| Jourdain (2015)74 | 41 (auto 33, allo 8) | < 20 | 1989–2007 | CR 35, no CR 6 | OS 46.3% (auto 48.5%; allo 37.5%) (5) |
| Hazar (2018)79 | 22 (auto 15, allo 7) | < 18 | 2006–2014 | CR 13, PR 3, Res 6 | EFS auto 53%; allo 86% (NR) |
| Rigaud (2019)75 | 21 (auto 13, allo 8) | < 18 | 2001–2011 | CR 12, no CR 9 | OS 54% (auto 54%; allo 50%) (5) |
| Burkhardt (2021)65 |
BL/BAL 254 (auto 64, allo 87) DLBCL 98 (auto 47, allo 25) |
< 18 | 2000 - NR | CR, PR, SD, PD |
BL/BAL: OS 28%; auto 44% allo 46% (8) DLBCL: OS 50%, (auto 68%; allo 55%) (8) |
| Woessman (2020)76 | 71 BL/BAL (auto 20, allo 26) | < 18 | 1986–2016 | CR | OS auto 25%; allo 58% (3) |
| Satwani (2015)80 | 5 tandem auto-allo | 7–33 | 2001–2011 | CR 2, PR 3 | 5/5 alive |
| Gardenswartz (2018)81 | 13 tandem auto-allo | 7–33 | NR | Chemosensitive disease | EFS 91% (NR) |
Abbreviations: Allo, allogeneic transplant; auto, autologous transplant; BAL, B acute leukemia; BL, Burkitt lymphoma; EFS, event free survival; CR, complete remission; DFS, disease free survival; DLBCL, diffuse large B-cell lymphoma; HSCT, hematopoietic stem cell transplant; NHL, non-Hodgkin lymphoma; NR, not reported; OS, overall survival; PD, progressive disease; PR, partial remission; Res, resistant; SD, stable disease.